This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Westin, P. Articles by Bergh, A. Search for Related Content PubMed PubMed Citation Articles by Westin, P. Articles by Bergh, A.

American Journal of Pathology, Vol 146, 1368-1375, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors

P Westin, P Stattin, JE Damber and A Bergh
Department of Pathology, University of Umea, Sweden.

Major differences in the long-term clinical response to castration therapy of prostatic carcinoma suggests intertumoral differences in cellular response and defines a need for identification of patients with an eventually positive outcome as well as those in need of additional treatment. Using morphometry, monoclonal antibodies against Bcl-2, c-myc, Ki-67, and p53 proteins, and an in situ method to visualize apoptotic cells, we examined the short-term response of prostatic tumors to castration in core biopsies from 18 prostatic cancer patients taken the day before and 7 days after castration. At the histological level, 3 tumors seemed practically unaffected by castration. In 15 tumors, castration induced vacuolization of tumor cell cytoplasm and decreases in nuclear area and Ki-67 index. In these 15 tumors, apoptotic index was significantly increased in 6, principally unaffected in 6, and decreased in 3. The 6 tumors responding with an increase in apoptotic index were WHO grade 1 or 2 and negative for p53, c-myc, and Bcl-2 or contained only few Bcl-2- or c-myc-positive tumor cells before therapy. The 12 tumors in which apoptotic index was unaffected or decreased were WHO grade 2 or 3 and immunopositive for one or more of p53, Bcl-2, and c-myc proteins before therapy. The Bcl-2 index was significantly increased in 10 patients. Prostatic tumors may respond in a variety of possibly predictable ways to castration therapy including a decrease in apoptotic index. The magnitude of these responses are not correlated in individual tumors, suggesting that the common classification of prostatic tumors as either androgen dependent (dying after castration) or independent (not responding at all to castration) may be an oversimplification.

This article has been cited by other articles:

				A. Johansson, S. H. Rudolfsson, P. Wikstrom, and A. Bergh Altered Levels of Angiopoietin 1 and Tie 2 Are Associated with Androgen-Regulated Vascular Regression and Growth in the Ventral Prostate in Adult Mice and Rats Endocrinology, August 1, 2005; 146(8): 3463 - 3470. [Abstract] [Full Text] [PDF]

				S. Gao, P. Lee, H. Wang, W. Gerald, M. Adler, L. Zhang, Y.-F. Wang, and Z. Wang The Androgen Receptor Directly Targets the Cellular Fas/FasL-Associated Death Domain Protein-Like Inhibitory Protein Gene to Promote the Androgen-Independent Growth of Prostate Cancer Cells Mol. Endocrinol., July 1, 2005; 19(7): 1792 - 1802. [Abstract] [Full Text] [PDF]

				H. Huang, D. C. Muddiman, and D. J. Tindall Androgens Negatively Regulate Forkhead Transcription Factor FKHR (FOXO1) through a Proteolytic Mechanism in Prostate Cancer Cells J. Biol. Chem., April 2, 2004; 279(14): 13866 - 13877. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				M. Rahman, H. Miyamoto, and C. Chang Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications Clin. Cancer Res., April 1, 2004; 10(7): 2208 - 2219. [Full Text] [PDF]

				M. M. Rahman, H. Miyamoto, H. Takatera, S. Yeh, S. Altuwaijri, and C. Chang Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells J. Biol. Chem., May 23, 2003; 278(22): 19619 - 19626. [Abstract] [Full Text] [PDF]

				M. M. Rahman, H. Miyamoto, H. Lardy, and C. Chang Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells PNAS, April 29, 2003; 100(9): 5124 - 5129. [Abstract] [Full Text] [PDF]

				J. Kotzerke, J. E. Gschwend, and B. Neumaier PET for Prostate Cancer Imaging: Still a Quandary or the Ultimate Solution? J. Nucl. Med., February 1, 2002; 43(2): 200 - 202. [Full Text] [PDF]

				K. Kimura, M. Markowski, C. Bowen, and E. P. Gelmann Androgen Blocks Apoptosis of Hormone-dependent Prostate Cancer Cells Cancer Res., July 1, 2001; 61(14): 5611 - 5618. [Abstract] [Full Text] [PDF]

				S. Signoretti, R. Montironi, J. Manola, A. Altimari, C. Tam, G. Bubley, S. Balk, G. Thomas, I. Kaplan, L. Hlatky, et al. Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer J Natl Cancer Inst, December 6, 2000; 92(23): 1918 - 1925. [Abstract] [Full Text] [PDF]

				J. E. Gschwend, W. R. Fair, and C. T. Powell Bryostatin 1 Induces Prolonged Activation of Extracellular Regulated Protein Kinases in and Apoptosis of LNCaP Human Prostate Cancer Cells Overexpressing Protein Kinase Calpha Mol. Pharmacol., June 1, 2000; 57(6): 1224 - 1234. [Abstract] [Full Text]

				R. Yu, S. Mandlekar, S. Ruben, J. Ni, and A-N. T. Kong Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Androgen-independent Prostate Cancer Cells Cancer Res., May 1, 2000; 60(9): 2384 - 2389. [Abstract] [Full Text]

				D. I. Quinn, S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, et al. Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy Cancer Res., March 1, 2000; 60(6): 1585 - 1594. [Abstract] [Full Text]

				D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde, and H. I. Scher Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence J Natl Cancer Inst, November 3, 1999; 91(21): 1869 - 1876. [Abstract] [Full Text] [PDF]

				N. Craft, C. Chhor, C. Tran, A. Belldegrun, J. DeKernion, O. N. Witte, J. Said, R. E. Reiter, and C. L. Sawyers Evidence for Clonal Outgrowth of Androgen-independent Prostate Cancer Cells from Androgen-dependent Tumors through a Two-Step Process Cancer Res., October 1, 1999; 59(19): 5030 - 5036. [Abstract] [Full Text] [PDF]

				M. Dahmoun, K. Boman, S. Cajander, P. Westin, and T. Bäckström Apoptosis, Proliferation, and Sex Hormone Receptors in Superficial Parts of Human Endometrium at the End of the Secretory Phase J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1737 - 1743. [Abstract] [Full Text]

				D. A. Knee, B. A. Froesch, U. Nuber, S. Takayama, and J. C. Reed Structure-Function Analysis of Bag1 Proteins. EFFECTS ON ANDROGEN RECEPTOR TRANSCRIPTIONAL ACTIVITY J. Biol. Chem., April 13, 2001; 276(16): 12718 - 12724. [Abstract] [Full Text] [PDF]